Daily English Article — September 17, 2026

A widely used antibiotic called cefepime has been linked to a higher risk of death in a major new study published in JAMA Network Open. Cefepime is a broad-spectrum antibiotic commonly administered by injection in hospital settings to treat serious bacterial infections, including pneumonia, urinary tract infections, skin infections, and meningitis. The drug is well established in clinical medicine, but new evidence suggests its safety profile may warrant closer scrutiny than previously assumed.

The global study reviewed 110 randomized clinical trials involving more than 22,000 patients who received either cefepime or another beta-lactam antibiotic — a class that includes penicillins and cephalosporins. Patients in the trials were being treated for a range of conditions, including febrile neutropenia, a life-threatening medical emergency characterized by fever and dangerously low white blood cell counts, as well as pneumonia, severe bacterial infections, UTIs, and meningitis.

Across all trials, 778 deaths occurred among 11,726 patients given cefepime, representing 6.6% mortality, compared to 6.2% among those given alternative antibiotics. Using a Bayesian meta-analysis — a statistical method that quantifies the probability of an association — researchers determined a 94.4% probability that cefepime is linked to higher all-cause mortality. When analysis was restricted to 73 peer-reviewed published trials, that probability rose sharply to 98.6%, a striking figure that underscores the robustness of the finding.

The association between cefepime and increased mortality was more pronounced in adult patients than in children, and was especially strong among those treated for febrile neutropenia. Researchers explored several potential explanations, including drug levels insufficient to adequately combat the infection and the possibility of neurotoxicity — a phenomenon already documented in older patients and those with impaired kidney function, for whom cefepime's known side effects include confusion, seizures, and decreased consciousness.

Despite these concerning findings, the researchers stopped short of recommending that clinicians discontinue cefepime, recognizing its value as an effective broad-spectrum antibiotic for hospitalized patients. Instead, they called for updated clinical guidance and further research to clarify the drug's safety profile. The study highlights the importance of ongoing pharmacovigilance — the continuous monitoring of drug safety — and raises broader questions about the assumed safety of antibiotics that have been in widespread use for decades.

Nintendo has shared a series of developer interviews ahead of the release of Fire Emblem: Fortune's Weave, offering a behind-the-scenes look at the creative decisions that shaped the game. The interviews revealed insights into the game's central themes — particularly family — and how the development team deliberately sought to differentiate Fortune's Weave from its highly influential predecessor, Fire Emblem: Three Houses, while still drawing heavily on that game's narrative structure as a foundation.

One of the most surprising revelations from the interviews was that the game's cast of protagonists was almost dramatically larger. Producer Genki Yokota disclosed that the team originally conceived a bold plan to feature eight story perspectives — more than double the three that defined Three Houses. The ambition was to surpass the earlier game in every conceivable dimension. However, this proved unworkable in practice, and the number was scaled back to four main protagonists whose parallel stories players can explore.

Even with four protagonists, the developers felt something essential was missing: a narrative element that could bring all the individual storylines together into a unified whole. This led to the creation of Eshmel, a fifth protagonist who serves as the player's initial point-of-entry character, functioning in a role broadly analogous to Byleth in Three Houses. Director Toshiyuki Kusakihara explained that Eshmel was necessary to provide a broader perspective and to ensure the separate stories converge meaningfully rather than remaining disconnected threads.

The interviews also touched on another notable departure for the franchise: the introduction of firearms. Fortune's Weave is the first entry in the long-running Fire Emblem series to feature guns, and while the developers declined to fully explain the narrative reasoning, they were emphatic that the decision was not driven by novelty. Producer Masahiro Higuchi suggested that as players progress, the story itself will illuminate why such weapons exist in the game's world — a hint that the game's time travel element may be central to the explanation.

The fate of the four protagonists originally planned beyond the final four remains unknown. The development team did not clarify whether those characters were repurposed as recruitable party members, scrapped entirely, or potentially held back for future downloadable content. With Nintendo hosting a dedicated Nintendo Direct for Fortune's Weave on August 4th, fans anticipate further revelations about the game's expansive cast and world ahead of its launch.